Most "best edibles for pain" lists treat pain as one problem with one answer, usually a 10mg gummy with some turmeric dusted on it so the label can say "recovery." Pain does not work that way. Arthritis pain, nerve pain, and a wrecked lower back run on different biology, respond to different cannabinoid ratios, and carry wildly different levels of research support. A product that earns its price for one can be a waste of money for another.
So this ranking is organized by pain type. Three buckets: inflammatory, neuropathic, and musculoskeletal. If you want the clinical version of this taxonomy (four buckets: nociceptive, neuropathic, nociplastic, and mixed), our chronic pain overview goes deeper. The three-way split below is the shopper's version of the same map. Figure out which bucket your pain lives in, then read that section. Reading all three is fine too, but buying for the wrong bucket is how people end up concluding edibles "don't work" after one $30 experiment.
Which type of pain do you have?
Inflammatory pain comes from tissue irritation and immune activity: arthritis, endometriosis, tendonitis, post-workout joint flares. It tends to throb, swell, and worsen with use of the affected area.
Neuropathic pain comes from damaged or misfiring nerves: diabetic neuropathy, sciatica, post-herpetic pain, chemo-induced nerve damage. Burning, tingling, electric. This is the category with the deepest trial record, covered in full on our neuropathic pain page. Fibromyalgia is technically its own thing (nociplastic, meaning the pain-processing system itself is dysregulated), but for product selection it behaves closer to the neuropathic bucket than anything else. Migraine is another crossover case with its own page and its own dosing logic.
Musculoskeletal pain is the everyday heavyweight: lower back pain, neck strain, old injuries that report for duty every morning. It got the biggest research upgrade of any category in 2025, more on that below.
Best for inflammatory pain
Papa & Barkley Releaf Gummies, 1:3 THC:CBD ($28). The ratio is the point. Inflammatory conditions respond to CBD's action on inflammatory signaling, with a low THC floor for the pain itself. The Sativex rheumatoid arthritis trial (Blake 2006), still the only randomized trial in RA, used a roughly balanced oromucosal spray and found improvements in pain on movement and sleep quality. Releaf leans harder into CBD than that trial did, which fits daytime use. You get meaningful cannabinoid content without spending the afternoon on the couch. The catch: at $28 for 100mg total cannabinoids, you are paying 28 cents a milligram. That is fragrance-counter pricing for molecules that cost pennies to produce. Whether the process earns that price is the question our Papa & Barkley review takes up.
Wyld Pear Gummies, 1:1 THC:CBG ($25). CBG is the interesting one here. The anti-inflammatory case for it rests on preclinical work, not human trials, so price the CBG at zero when deciding whether this is worth $25. What earns Wyld the slot is execution: consistent dosing piece to piece, real fruit flavor instead of the medicinal pear-adjacent syrup most brands use, and batch COAs you can actually find. Honest formulation, thin evidence base. We can live with that combination when the THC is doing verified work regardless.
Best for neuropathic pain
Nerve pain needs THC. That is the uncomfortable finding running through the neuropathic literature: the Abrams 2007 HIV neuropathy trial and the Wilsey trials both found pain reduction from THC-containing cannabis, with the Wilsey work showing even low doses performed. Those trials used inhaled cannabis, so edibles borrow the cannabinoid logic from those trials with a different delivery method, a distinction we spell out in the condition page. The practical translation: skip the CBD-only products for nerve pain and pick something balanced.
1906 Relief, 5mg THC / 25mg CBD per pill ($25). A swallowable pill instead of a candy, which sounds joyless until you have nerve pain at work and want a dose you can take without unwrapping something that smells like a Jolly Rancher. The heavy CBD load buffers the THC, and the pill format gives the most consistent onset of anything in this ranking.
Wana Quick Midnight 1:1, 5mg THC / 5mg CBD ($22). The nano-emulsified fast-acting pick. Onset in 15 to 20 minutes instead of the usual hour-plus, which matters for neuropathic flares that arrive on their own schedule. The tradeoff is duration: expect 2 to 3 hours instead of 6. Buy this for breakthrough pain, not for all-day coverage.
Best for musculoskeletal pain
This category used to run entirely on observational data and patient surveys. Then September 2025 happened: the VER-01 phase 3 trial (Karst et al., Nature Medicine) tested a THC-dominant oral cannabis extract in 820 adults with chronic low back pain and found clinically meaningful pain reduction against placebo. First high-quality randomized trial to show a cannabis product treats chronic pain, and it used an oral format, the same delivery route as every product on this page. Our lower back pain page breaks down the trial and what it does and does not prove.
Level Protab, 25mg THC per tablet ($24 for 10). The value monster of licensed cannabis: under 10 cents per milligram, a third of what the gummy brands charge, in a scored tablet you can split into 12.5mg halves. VER-01 used a THC-dominant extract at doses well above the 5mg gummy standard, and Protab is the closest retail analog to that profile. To be clear about who this is for: 25mg is a serious dose. Split the tablet, start with half or less, and read our dosing guide before treating this like a starter product.
Kiva Camino Gummies, 5mg THC ($18). The entry point. Camino is everywhere, reliably dosed, and 5mg is the right opening move for anyone new to THC. Our complaint is the same one we have with most of the category: 5mg is often not enough for real musculoskeletal pain, and Kiva knows it. The low dose serves the cannabis-naive customer and the brand's liability comfort more than it serves your back. Buy it to establish your tolerance, then move up.
What we skipped
Anything marketed as a "recovery" or "relief" gummy where the formulation is identical to the brand's regular line plus a botanical garnish. Turmeric at the milligram levels found in gummies does nothing measurable. Same for the hemp-derived THC products still floating around ahead of the November federal deadline; untested supply chains and pain treatment are a bad pairing, and our medical use guide explains what to demand from any product you are taking daily.
One more omission worth naming: topicals. People with arthritis ask about THC balms constantly. Different product class, different absorption story, not an edible, so not ranked here.
Dosing for pain is different from dosing for fun
Recreational dosing chases a peak. Pain dosing chases a floor: steady, repeatable relief at the lowest dose that produces it. That usually means scheduled low doses instead of reactive large ones, and it means tracking what you took and what happened for at least two weeks before judging any product. The full protocol lives in the dosing guide and the condition pages linked throughout, each of which carries dose ranges pulled from the actual trial literature instead of from package labels. Package labels are marketing. The trials are not.